BiondVax Pharmaceuticals (NASDAQ:BVXV) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a note issued to investors on Friday.
Shares of BiondVax Pharmaceuticals (BVXV) traded down $0.31 during trading on Friday, reaching $5.51. The company had a trading volume of 10,275 shares, compared to its average volume of 14,009. BiondVax Pharmaceuticals has a one year low of $3.04 and a one year high of $10.75.
COPYRIGHT VIOLATION WARNING: This piece was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/03/biondvax-pharmaceuticals-bvxv-stock-rating-lowered-by-valuengine.html.
BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company. The Company holds a worldwide exclusive license granted by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, Israel, for developing, manufacturing and commercializing the flu vaccine. BiondVax Pharmaceuticals Ltd develops a biopharmaceutical universal flu vaccine, designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for BiondVax Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.